Owlstone Medical Secures $27M in Series E Funding to Advance Breath-Based Diagnostics

Owlstone Medical has announced a significant milestone in its growth trajectory with a $27 million (approximately £22 million) first close of its Series E financing round. The investment, led by Ventura Capital and supported by notable investors including Aviva Ventures, Horizons Ventures, and the Gates Foundation, marks a crucial advancement in the field of breath-based diagnostics.

The funding will drive the development and commercialization of Owlstone's innovative Breath Biopsy platform, focusing on diagnostic tests and point-of-care devices across multiple critical health areas. The company's primary focus includes early detection solutions for lung cancer, which remains the leading cause of cancer-related deaths globally, as well as tests for liver disease and digestive disorders.

Mo El Husseiny, Founder and Managing Partner at Ventura Capital, expressed confidence in the company's direction, stating, "Owlstone is driving progress in the space." This sentiment was echoed by Tom Grant, Head of Venture Investments at Aviva Investors, who noted, "Owlstone has made tremendous progress since their last fundraise."

Billy Boyle, co-founder and CEO at Owlstone Medical, outlined the company's plans for the funding: "The funds will enable us to advance clinical trials and commercialize our breath tests." The company's approach centers on its proprietary Breath Biopsy® platform and VOC Atlas® database, which have demonstrated promising results in clinical applications.

Among the company's current development initiatives are the lung cancer screening test, which aims to provide early detection capabilities for the disease's most treatable stages; the LIBRA test, designed to assess and monitor chronic liver diseases; and the OMED Health Breath Analyzer, which focuses on digestive disease diagnosis and monitoring. These technologies leverage volatile organic compound (VOC) analysis, a cutting-edge approach that can detect disease biomarkers in exhaled breath.

The breath-based diagnostic market has seen increasing interest from healthcare providers and investors, as these non-invasive tests offer potential advantages in terms of patient comfort, cost-effectiveness, and rapid results. Owlstone's technology could particularly impact communities with limited access to traditional diagnostic facilities, aligning with global efforts to improve healthcare accessibility.

This funding round represents a critical step toward Owlstone's goal of revolutionizing disease detection and precision medicine through innovative breath-based diagnostics, potentially transforming how various diseases are diagnosed and monitored in clinical settings.

Click here for the original news story.